Secukinumab as biological treatment for psoriatic arthritis in real clinical practice José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;

Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;